Fisetin
- Generic Name
- Fisetin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10O6
- CAS Number
- 528-48-3
- Unique Ingredient Identifier
- OO2ABO9578
Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Ove Andersen
- Target Recruit Count
- 60
- Registration Number
- NCT06431932
Fisetin to Reduce Senescence and Mobility Impairment in PAD
- Conditions
- Peripheral Arterial DiseaseAgingPeripheral Vascular DiseasesWalking, DifficultyClaudication
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 34
- Registration Number
- NCT06399809
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Prevention of Frailty with Fisetin and Exercise (PROFFi) in Breast Cancer Survivors
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) V8Anatomic Stage II Breast Cancer AJCC V8Anatomic Stage III Breast Cancer AJCC V8Early Stage Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Educational InterventionOther: Exercise InterventionOther: Physical Performance TestingDrug: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 164
- Registration Number
- NCT06113016
- Locations
- 🇺🇸
UCLA Health Cancer Care in Alhambra, Alhambra, California, United States
🇺🇸UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California, United States
🇺🇸UCLA Health Burbank Primary & Specialty Care, Burbank, California, United States
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionDrug: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT05595499
- Locations
- 🇺🇸
UCLA Health Cancer Care in Alhambra, Alhambra, California, United States
🇺🇸UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California, United States
🇺🇸UCLA Health Burbank Primary & Specialty Care, Burbank, California, United States
Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency
- Conditions
- Common Variable ImmunodeficiencyInterstitial Lung Disease Due to Systemic Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Avni Joshi
- Target Recruit Count
- 20
- Registration Number
- NCT05593588
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair
- Conditions
- Meniscus TearMeniscus; DerangementMeniscus LesionMeniscus Disorder
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Austin V Stone
- Target Recruit Count
- 38
- Registration Number
- NCT05505747
- Locations
- 🇺🇸
UK Healthcare at Turfland, Lexington, Kentucky, United States
GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression
- Conditions
- Knee OsteoarthritisObeseDepression
- Interventions
- Drug: Placebo oral capsuleBehavioral: GetHealthy-OA mind-body programBehavioral: Health education booklet
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Cale Andrew Jacobs, PhD
- Registration Number
- NCT05482672
- Locations
- 🇺🇸
UK HealthCare Joint Reconstruction and Replacement, Lexington, Kentucky, United States
🇺🇸UK Healthcare at Turfland, Lexington, Kentucky, United States
A Study of Fisetin to Treat Carpal Tunnel Syndrome
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Peter C. Amadio, M.D.
- Target Recruit Count
- 40
- Registration Number
- NCT05416515
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
- Conditions
- Femoroacetabular Impingement
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 68
- Registration Number
- NCT05025956
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04815902
- Locations
- 🇺🇸
The Steadman Clinic, Vail, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.